Association of CFTR gene mutation with bronchial asthma

Indian Journal of Medical Research

Volumn 135, Issue 4, 2012, Pages 469-478

  Maurya, Nutan ^a   Awasthi, Shally ^a   Dixit, Pratibha ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Asthma; CFTR; Cystic fibrosis; Heterozygous; Modifier genes; Phenotype

Indexed keywords

GLUTATHIONE TRANSFERASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; MANNOSE BINDING LECTIN; RANTES; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA;

ASTHMA; CHROMOSOME 7; CYSTIC FIBROSIS; CYTOKINE RELEASE; DISEASE ASSOCIATION; EXON; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INDIA; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW;

ASTHMA; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENES, MODIFIER; HETEROZYGOTE; HUMANS; INDIA; MUTATION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84861922716     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Gadsby DC, Nairn AC. Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol Rev 1999; 79(Suppl1):S77-S107.
2. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999; 79: S23-S45.
3. Welish MJ, Tsui LC, Boat TF, Beaudet AL. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editor. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 1995. p. 3799-3876.
4. Bombieri C, Benetazzo M, Saccomani A, Belpinati F, Gile LS, Luisetti M, et al. Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. Hum Genet 1998; 103: 718-722.
5. Girodon E, Cazeneuve C, Lebargy F, Chinet T, Costes B, Ghanem N, et al. CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet 1997; 5: 149-155.
6. Mller PW, Hamosh A, Macek MJ, Greenberger PA, MacLean J, Walden SM, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet 1996; 59:45-51.
7. Dahl M, Tybjaerg Hansen A, Lange P, Nordestgaard BG. Delta F508 heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet 1998; 351: 1911-1913.
8. Tzetis M,Efthymiadou A, Strofalis S, Psychou P, Dimakou A, Pouliou E. CFTR gene mutations - including three novel nucleotide substitutions - and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. Hum Genet 2001; 108: 216-221.
9. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z. Identifcation of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 8: 1066-1073.
10. Fanen P, Hasnain A. Cystic Fibrosis and CFTR Gene. Atlas Genet Cytogenet Oncol Haematol; 2001. Available from: http://AtlasGeneticsOncology.org/Educ/CistFibID30032ES.html, accessed on January 3,2011.
11. Gadsby DC, Vergani P, Csanády L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 2006; 440: 477-483.
12. Garry R. Modifer genetics: Cystic fibrosis. Hum Genet 2005; 6: 237-260.
13. Bradbury NA, Jilling T, Berta G, Sorscher EJ, Bridges RJ, Kirk KL. Regulation of plasma membrane recycling by CFTR. Science 1992; 256: 530-532.
14. Donaldson SH, Boucher RC. Update on pathogenesis of cystic fibrosis lung disease. Curr Opin Pulm Med 2003; 9: 486-491.
15. Tousson A, Van Tine BA, Naren AP, Shaw GM, Schwiebert LM. Characterization of CFTR expression and chloride channel activity in human endothelia. Am J Physiol 1998; 275: C1555-C1564.
16. Robert R, Thoreau V, Norez C, Cantereau A, Kitzis A, Mettey Y, et al. Regulation of the cystic fibrosis transmembrane conductance regulator channel by beta-adrenergic agonists and vasoactive intestinal peptide in rat smooth muscle cells and its role in vasorelaxation. J Biol Chem 2004; 279: 21160-2168.
17. Robert R, Norez C, Becq F. Disruption of CFTR chloride channel alters mechanical properties and cAMP-dependent Cl2 transport of aortic smooth muscle cells. J Physiol 2005; 568: 483-495.
18. Vandebrouck C, Melin P, Norez C, Robert C, Guibert C, Mettey Y, et al. Evidence that CFTR is expressed in rat tracheal smooth muscle cells and contributes to bronchodilation. Respir Res 2006; 7: 113.
19. Koch C, Cuppins H, Rainisio M, Madessani U, Harms H, Hodson M, et al. Investigators of the ERCF. European Epidemiologic Registory of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 2001; 31: 1-12.
20. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000; 67: 117-33.
21. Mckle JE, Cutting GR. Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am 2000; 84: 597-607.
22. Lording A, McGaw J, Dalton A, Beal G, Everard M, Taylor CJ. Pulmonary infection in mild variant cystic fibrosis: Implications for care. J Cyst Fibros 2006; 5: 101-104.
23. Dreyfus DH, Bethel R, Gelfand EW. Cystic fibrosis 3849+10 KbC>T mutation associated with severe pulmonary disease and male fertility. Am J Respir Crit Care Med 1996; 153: 858-860.
24. Chris C. Mechanisms of asthma. Medicine 2008; 36: 177-80.
25. Holgate ST, Davies DE, Lackie PM, Wilson SJ, Puddicombe SM, Lordan JL. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000; 105: 193-204.
26. Von Mutius E, Sears MR. Risk factors for development of asthma. Eur Respir Mon 2003; 8: 57-73.
27. Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST. Airway remodelling in asthma - new insights. J Allergy Clin Immunol 2003; 111: 215-222.
28. Holgate ST, Peter ML, Peter HH, William RR, Sarah MP, Audrey R. Invited lecture: activation of the epithelial mesenchymal trophic unit in the pathogenesis of asthma. Int Arch Allergy Immunol 2001; 124: 253-258.
29. Garry R. Cutting modifer genes in Mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci 2010; 1214: 57-69.
30. Merlo CA, Boyle MP. Modifer genes in cystic fibrosis lung disease. J Lab Clin Med 2003; 141: 237-41.
31. Redington AE, Madden J, Frew A J, Djukanovic R, Roche WR, Holgate ST, et al. Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fuid. Am J Respir Crit Care Med 1997; 156: 642-647.
32. Aittoniemi J, Soranummi H, Rovio AT, Hurme M, Pessi T, Nieminen M, et al. Mannose-binding lectin 2 (MBL2) gene polymorphism in asthma and atopy among adults. Clin Exp Immunol 2005; 142: 120-124.
33. Heffer E, Berry M, Pavord ID. Tumor necrosis factor-alpha: a promising therapeutic target for asthma? BioDrugs 2007; 21: 345-349.
34. Szczepankiewicz A, Breborowicz A, Sobkowiak P, Kramer L, Popiel A. Role of ADRB2 gene polymorphism in asthma and response to beta (2)-agonists in Polish children. J Appl Genet 2009; 50:275-281.
35. Lázaro C, de Cid R, Sunyer J, Soriano J, Giménez J, Álvarez M, et al. Missense mutations in the cystic fibrosis gene in adult patients with asthma. Hum mutat 1999; 14: 510-519.
36. Dahl J, Tybjaerg-Hansen A, Lange P, Nordestgaard BG. Asthma and COPD in cystic fibrosis intron-8 5T carriers. A population- based study. Respir Res 2005; 6: 113.
37. Ngiam NSP, Chong SS, Shek LPC, Goh DLM, Ong KC, Chng SY, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Asians with chronic pulmonary disease: A pilot study. J Cyst Fibros 2006; 5: 159-164.
38. Schroeder SA, Gaughan DM, Swift M. Protection against bronchial asthma by CFTR DF508 mutation: a heterozygote advantage in cystic fibrosis. Nat Med 1995; 1: 703-705.
39. Mennie M, Gilfllan A, Brock DJ, Liston WA. Heterozygotes for the delta DF508 cystic fibrosis allele are not protected against bronchial asthma. Nat Med 1995; 1: 978-979.
40. Lowenfels AB, Maisonneuve P, Palys B, Schöni MH, Redemann B. Delta F508 heterozygosity and asthma. Lancet 1998; 352: 985-987.
41. Kauffmann F, Chomel JC, Kitzis A, Feingold J. Delta F508 heterozygosity and asthma. EGEA Co-operative Group. Lancet 1998; 352: 985-986.
42. de Cid R, Chome JC, Lazaro C, Sunyer J, Baudis M, Casals T, et al. CFTR and asthma in the French EGEA study. Eur J Hum Genet 2001;9: 67-69.
43. Munthe-Kaas MC, Lodrup Carlsena KC, Carlsen KH, Skinningsrud B, Haland G, Devulapallia CS, et al. CFTR gene mutations and asthma in the Norwegian Environment and Childhood Asthma study. Respir Med 2006; 100: 2121-2122.
44. Douros K, Loukou I, Doudounakis S, Tzetis M, Priftis KN, Kanavakis E. Asthma and pulmonary function abnormalities in heterozygotes for cystic fibrosis transmembrane regulator gene mutations. Int J Clin Exp Med 2008; 1: 345-349.
45. Kim KW, Lee JH, Lee MG, Kim KH, Sohn MH, Kim KE. Association between cystic fibrosis transmembrane conductance regulator gene mutations and susceptibility for childhood asthma in Korea. Yonsei Med J 2010; 51: 912-917.
46. Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 1993; 3: 151-156.
47. Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (TG) m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 1998; 101: 487-496.
48. Niksic M, Romano M, Buratti E, Pagani F, Baralle FE. Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR exon 9. Hum Mol 1999; 8: 2339-2349.
49. Noone PG, Pue CA, Zhou Z, Friedman KJ, Wakeling EL, Ganeshananthan J, et al. Lung disease associated with the IVS8 5T allele of the CFTR Gene. Am J Respir Crit Care Med 2000; 162: 1919-1924.
50. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 2007; 261: 5-16.
51. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998; 95: 1005-1015.
52. Matsui H, Randell SH, Peretti SW, Davis CW, Boucher RC. Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Invest 1998; 102: 1125-1131.
53. Regnis JA, Robinson M, Bailey DL, Cook P, Hooper P,Chan HK, et al. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med 1994;150:66-71.
54. Ratjen FA. Cystic fibrosis: Pathogenesis and future treatment strategies. Respir Care 2009; 54: 595-602.
55. Balfour-Lynn IM, Elborn JS. "CF asthma": what is it and what do we do about it? Thorax 2002; 57: 742-748.
56. Koch C, McKenzie SG, Kaplowitz H, Hodson ME, Harms HK, Navarro J, et al. International practice patterns by age and severity of lung disease in cystic fibrosis: data from the Epidemiologic Registry of Cystic Fibrosis (ERCF). Pediatr Pulmonol 1997; 24: 147-154.
57. Balfour IM. Asthma in cystic fibrosis. J R Soc Med 2003; 96: 30-34.
58. Kabra SK, Kabra M, Lodha R, Shastri S, Ghosh M, Pandey RM. Clinical profle and frequency of delta f508 mutation in Indian children with cystic fibrosis. Indian Pediatr 2003; 40: 612-619.
59. Kabra M, Ghosh M, Kabra SK, Khanna A, Verma IC. Delta F 508 molecular mutation in Indian children with cystic fibrosis. Indian J Med Res 1996; 104: 355-358.
60. Shastri SS, Kabra M, Kabra SK, Pandey RM, Menon PS. Characterisation of mutations and genotype-phenotype correlation in cystic fibrosis: experience from India. J Cyst Fibros 2008; 7: 110-115.
61. Kabra M, Kabra SK, Ghosh M, Khanna A, Arora S, Menon PS, et al. Is the spectrum of mutations in Indian patients with cystic fibrosis different? Am J Med Genet 2000; 93: 161-163.
62. Kapoor S, Shastri M, Kabra S, Kabra V, Ramachandran S, Arora P, et al. Carrier frequency of F508del mutation of cystic fibrosis in Indian population. J Cyst Fibros 2003; 5: 43-46.
63. Ashavid TF, Dherai AJ, Kondkar AA, Raghavan R, Udani SV, Udwadia ZF, et al. Molecular diagnosis of cystic fibrosis in Indian patients - A preliminary report. J Assoc Physicians India 2003; 51: 345-348.
64. Ashavaid TF, Kondkar AA, Dherai A J, Raghavan R, Udani SV, Udwadia ZF, et al. Application of multiplex ARMS and SSCP/HD analysis in molecular diagnosis of cystic fibrosis in Indian patients. Mol Diagn 2005; 9: 59-66.
65. Powers CA, Potter EM, Wessel HU, Lioyd- Still JD. Cystic fibrosis in Asian Indians. Arch Pediatr Adolesc Med 1996; 150: 554-555.
66. Prasad R, Sharma H, Kaur G. Molecular basis of cystic fibrosis disease: An Indian perspective. Indian J Clin Biochem 2010; 25:335-341.